SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075%
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Sodium chloride and potassium chloride are electrolytes that maintain osmotic balance, fluid distribution, and proper cellular function. Sodium is the primary extracellular cation involved in fluid balance, nerve impulse transmission, and muscle contraction. Potassium is the major intracellular cation essential for cardiac, skeletal, and smooth muscle activity, and acid-base balance.
| Metabolism | Sodium and potassium are not metabolized; they are excreted unchanged primarily by the kidneys. |
| Excretion | Sodium and potassium ions are primarily excreted renally. Sodium elimination follows glomerular filtration with 99% tubular reabsorption, while potassium is filtered, then 90% is reabsorbed in proximal tubule and loop of Henle, with distal secretion regulated by aldosterone. Fecal excretion is minimal (<5%) under normal conditions. |
| Half-life | Sodium and potassium have no true terminal half-life as they are homeostatically regulated. In steady-state, sodium turnover half-life is approximately 2-3 weeks, while potassium has a faster turnover of about 40 hours in skeletal muscle. Clinically, redistribution after IV infusion occurs within hours, with renal excretion adapting rapidly. |
| Protein binding | Sodium and potassium ions are not significantly protein-bound; binding <1%. |
| Volume of Distribution | Sodium Vd is approximately 0.20-0.25 L/kg, equating to extracellular fluid volume. Potassium Vd is larger, approximately 0.5-0.6 L/kg, mainly distributing into intracellular fluid (98% of body potassium). |
| Bioavailability | Oral sodium chloride: nearly 100% absorbed. Oral potassium chloride: bioavailability 70-90% (due to some fecal loss and absorption variability). IV administration: 100% bioavailable. |
| Onset of Action | IV infusion: immediate electrolyte distribution and hemodynamic effects (within seconds to minutes). Rapid correction of hyponatremia or hypokalemia begins within minutes of infusion initiation. |
| Duration of Action | Duration depends on renal function and ongoing losses. For IV rehydration, effects last 2-6 hours; for potassium replacement, duration is until cellular uptake and renal excretion, typically 4-8 hours. Prolonged in renal impairment. |
| Molecular Weight | Sodium chloride (NaCl): 58.44 Da; Potassium chloride (KCl): 74.55 Da; Combined solution weighted average: approximately 60.5 Da (assuming 0.9% NaCl and 0.075% KCl w/v). |
Intravenous infusion; typical adult dose is 1-2 mL/kg/hr adjusted based on serum electrolyte levels and fluid status. For maintenance, 30 mL/kg/day of 0.9% sodium chloride with 0.075% potassium chloride (KCl 10 mEq/L) at a rate of 100-125 mL/hr. Not to exceed 20 mEq KCl per hour.
| Dosage form | INJECTABLE |
| Renal impairment | Contraindicated in severe renal impairment (eGFR <30 mL/min/1.73m²) due to risk of hyperkalemia. For eGFR 30-60 mL/min/1.73m², reduce dose by 25-50% and monitor serum potassium closely. In oliguric patients, avoid unless documented hypokalemia and careful monitoring. |
| Liver impairment | No specific dose adjustment recommended per Child-Pugh class. Caution in severe hepatic impairment (Child-Pugh C) due to potential electrolyte disturbances; monitor serum potassium and chloride levels frequently. |
| Pediatric use | Weight-based: Intravenous infusion at 0.5-1 mL/kg/hr for maintenance, with potassium chloride at 0.5-1 mEq/kg/day. Do not exceed 0.5 mEq/kg/hr or 20 mEq/100 mL infusion fluid. Adjust based on serum electrolytes and hydration status. For neonates, use with caution and monitor renal function. |
| Geriatric use | Start at lower end of dosing range (1 mL/kg/hr) with careful monitoring of renal function and serum electrolytes due to age-related decline in renal function and increased risk of hyperkalemia. Avoid use in patients with eGFR <30 mL/min/1.73m². |
| 1st trimester | Sodium chloride and potassium chloride are physiological electrolytes. No evidence of teratogenicity. Use for correction of electrolyte imbalances is considered safe. No dose adjustment required. |
| 2nd trimester | Safe for use in pregnancy when clinically indicated. Monitor renal function and serum electrolytes, especially in preeclampsia or conditions affecting fluid balance. |
| 3rd trimester | Safe for use, but caution in hypertensive disorders or fluid overload. Potassium accumulation may occur in renal impairment or with certain medications (e.g., ACE inhibitors). |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | Sodium and chloride readily cross the placenta via active transport and diffusion; potassium crosses via active transport. Fetal serum levels are tightly regulated. No known adverse effects at therapeutic doses. |
| Breastfeeding | Sodium and potassium are normal constituents of breast milk. Administration of intravenous fluids containing these electrolytes does not pose a risk to the infant. However, maternal electrolyte imbalances should be corrected appropriately to avoid milk composition changes. |
| Lactation Rating | Safe |
| Teratogenic Risk | Sodium chloride 0.9% and potassium chloride 0.075% are physiologic electrolytes; no teratogenic effects reported. No known fetal risk at any trimester when used as indicated. |
| Fetal Monitoring | Monitor serum electrolytes (sodium, potassium) and fluid balance, especially in cases of prolonged infusion or patient with renal/cardiac impairment. Assess for signs of hypernatremia or hyperkalemia. |
| Fertility Effects | No known effects on fertility. Not studied but expected to have no impact due to physiologic nature. |
■ FDA Black Box Warning
None
| Common Effects | fluid replacement |
| Serious Effects |
HyperkalemiaHypernatremiaSevere renal impairment with oliguria or anuria (unless concurrent dialysis)Hypersensitivity to any component
| Precautions | Use with caution in patients with heart failure, renal impairment, adrenal insufficiency, or cirrhosis with ascites., Monitor serum electrolytes, fluid balance, and renal function during therapy., Avoid rapid infusion or excessive volume to prevent fluid overload, hyperkalemia, or hypernatremia., Potassium-containing solutions should be administered with caution in patients on potassium-sparing diuretics or ACE inhibitors. |
| Food/Dietary | Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, potatoes, spinach, avocados) and salt substitutes containing potassium chloride, as they may increase risk of hyperkalemia. |
| Clinical Pearls | Contains 0.9% sodium chloride (154 mEq/L Na+ and Cl-) and 0.075% potassium chloride (10 mEq/L K+). Use for replacement therapy in hypokalemia with concurrent sodium/volume depletion. Rate and volume must be adjusted based on serum electrolytes and fluid status. Monitor for hyperkalemia, especially in renal impairment. Avoid in patients with hyperkalemia, hypernatremia, or fluid overload. |
| Patient Advice | This solution contains potassium and salt. It is given intravenously to correct low potassium levels and to replace fluids. · Tell your healthcare provider if you have kidney problems, heart disease, or are on a low-salt diet. · Report any symptoms such as muscle weakness, irregular heartbeat, numbness or tingling, or swelling. · Do not consume salt substitutes or high-potassium foods without consulting your doctor. · This medication will be monitored with regular blood tests. |
Loading safety data…